Effects of exercise training on circulating levels of Dickkpof-1 and secreted frizzledrelated protein-1 in breast cancer survivors: A pilot single-blind randomized controlled trial

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Kim, Tae Ho ^a,b   Chang, Jae Seung ^a,b   Park, Kyu Sang ^a   Park, Jeeyeon ^c   Kim, Nahyun ^d   Lee, Jong In ^a   Kong, In Deok ^a,b  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Kyungsung University   (South Korea)

^d Keimyung University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; DICKKOPF 1 PROTEIN; INSULIN; LEPTIN; SECRETED FRIZZLED RELATED PROTEIN 1; DKK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVOR; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED BODY FAT PERCENTAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HUMAN; INTRAPERITONEAL FAT; LEPTIN ADIPONECTIN RATIO; MOLECULAR DYNAMICS; MUSCLE EXERCISE; MUSCLE FLEXIBILITY; MUSCLE STRENGTH; MUSCULOSKELETAL SYSTEM PARAMETERS; OUTCOME ASSESSMENT; PHYSICAL PARAMETERS; PILOT STUDY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; BLOOD; BODY COMPOSITION; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RISK FACTOR; SURVIVOR;

ADULT; BIOMARKERS; BODY COMPOSITION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; SURVIVORS;

EID: 85012909494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0171771     Document Type: Article

References (54)

1. Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, et al. Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer. 2012;118:2207-2216. doi: 10.1002/cncr.27469 PMID: 22488695
2. Loprinzi PD, Cardinal BJ. Effects of physical activity on common side effects of breast cancer treatment. Breast Cancer. 2012;19:4-10. doi: 10.1007/s12282-011-0292-3 PMID: 21725654
3. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol. 2005;23:3830-3842. doi: 10.1200/JCO.2005.02.148 PMID: 15923576
4. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006;175:34-41. doi: 10.1503/cmaj.051073 PMID: 16818906
5. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4:
6. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11-26. doi: 10.1038/nrc3419 PMID: 23258168
7. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004;9:119-131. doi: 10.1023/B:JOMG.0000037157.94207.33 PMID: 15300008
8. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007;9:R63. doi: 10.1186/bcr1769 PMID: 17897439
9. Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJ, et al. Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta. 2014;1845:53-65. doi: 10.1016/j.bbcan. 2013.11.004 PMID: 24316024
10. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179-192. doi: 10.1038/nm.3074 PMID: 23389618
11. Gough NR. Focus issue: Wnt and beta-catenin signaling in development and disease. Sci Signal. 2012;5:eg2. doi: 10.1126/scisignal.2002806 PMID: 22234609
12. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469-7481. doi: 10.1038/sj.onc.1210054 PMID: 17143291
13. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13:767-779. doi: 10.1038/nrm3470 PMID: 23151663
14. Sheldahl LC, Park M, Malbon CC, Moon RT. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol. 1999;9:695-698. PMID: 10395542
15. Kuhl M, Sheldahl LC, Malbon CC, Moon RT. Ca (2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem. 2000;275:12701-12711. PMID: 10777564
16. Zhou SJ, Zhuo SR, Yang XQ, Qin CX, Wang ZL. Serum Dickkopf-1 expression level positively correlates with a poor prognosis in breast cancer. Diagn Pathol. 2014;9:161. doi: 10.1186/s13000-014-0161-4 PMID: 25116444
17. Rachner TD, Gobel A, Benad-Mehner P, Hofbauer LC, Rauner M. Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Lett. 2014;346:172-177. doi: 10.1016/j.canlet.2014.01.010 PMID: 24462802
18. Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene. 2004;23:8520-8526. doi: 10.1038/sj.onc.1207892 PMID: 15378020
19. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116:2627-2634. doi: 10.1242/jcs.00623 PMID: 12775774
20. Bernemann C, Hulsewig C, Ruckert C, Schafer S, Blumel L, Hempel G, et al. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Mol Cancer. 2014;13:174. doi: 10.1186/1476-4598-13-174 PMID: 25033833
21. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007;97:964-970. doi: 10.1038/sj. bjc.6603959 PMID: 17876334
22. Voorzanger-Rousselot N, Journe F, Doriath V, Body JJ, Garnero P. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int. 2009;84:348-354. doi: 10.1007/s00223-009-9225-y PMID: 19252761
23. Han SX, Zhou X, Sui X, He CC, Cai MJ, Ma JL, et al. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Oncotarget. 2015;6:19907-19917. doi: 10.18632/oncotarget.4529 PMID: 26101916
24. Rachner TD, Thiele S, Gobel A, Browne A, Fuessel S, Erdmann K, et al. High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer. 2014;14:649. doi: 10. 1186/1471-2407-14-649 PMID: 25182503
25. D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, et al. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med. 2016;213:827-840. doi: 10.1084/jem.20150950 PMID: 27045006
26. Kerschan-Schindl K, Thalmann MM, Weiss E, Tsironi M, Foger-Samwald U, Meinhart J, et al. Changes in serum levels of myokines and Wnt-antagonists after an ultramarathon race. PLoS One. 2015;10:e0132478. doi: 10.1371/journal.pone.0132478 PMID: 26147574
27. Bayod S, Mennella I, Sanchez-Roige S, Lalanza JF, Escorihuela RM, Camins A, et al. Wnt pathway regulation by long-term moderate exercise in rat hippocampus. Brain Res. 2014;1543:38-48. doi: 10. 1016/j.brainres.2013.10.048 PMID: 24183784
28. Irwin ML, American College of Sports Medicine. ACSM's guide to exercise and cancer survivorship. Champaign, IL: Human Kinetics; 2012.
29. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-381. PMID: 7154893
30. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Martin BS, et al. Effect of exercise training on Creactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun. 2005;19:381-388. doi: 10.1016/j.bbi.2005.04.001 PMID: 15922556
31. Winters-Stone KM, Dobek J, Bennett JA, Nail LM, Leo MC, Schwartz A. The effect of resistance training on muscle strength and physical function in older, postmenopausal breast cancer survivors: a randomized controlled trial. J Cancer Surviv. 2012;6:189-199. doi: 10.1007/s11764-011-0210-x PMID: 22193780
32. Chan DN, Lui LY, So WK. Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review. J Adv Nurs. 2010;66:1902-1914. doi: 10.1111/j.1365-2648.2010.05374.x PMID: 20626480
33. Riesco E, Choquette S, Audet M, Lebon J, Tessier D, Dionne IJ. Effect of exercise training combined with phytoestrogens on adipokines and C-reactive protein in postmenopausal women: a randomized trial. Metabolism. 2012;61:273-280. doi: 10.1016/j.metabol.2011.06.025 PMID: 21864865
34. Ryan AS, Nicklas BJ, Berman DM, Elahi D. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord. 2003;27:1066-1071. doi: 10.1038/sj.ijo.0802387 PMID: 12917712
35. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106-2111. doi: 10.1182/blood-2006-09-047712 PMID: 17068150
36. Zhou F, Meng S, Song H, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev. 2013;27:261-267. doi: 10.1016/j.blre. 2013.08.002 PMID: 24054128
37. Capietto AH, Kim S, Sanford DE, Linehan DC, Hikida M, Kumosaki T, et al. Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med. 2013;210:2257-2271. doi: 10.1084/jem.20130281 PMID: 24127488
38. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67:2517-2525. doi: 10.1158/0008-5472. CAN-06-3369 PMID: 17363569
39. Liu Y, Tang W, Xie L, Wang J, Deng Y, Peng Q, et al. Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis. Tumour Biol. 2014;35:3145-3154. doi: 10.1007/s13277-013-1411-x PMID: 24258111
40. Spillane M, Schwarz N, Willoughby DS. Upper-body resistance exercise augments vastus lateralis androgen receptor-DNA binding and canonical Wnt/beta-catenin signaling compared to lower-body resistance exercise in resistance-trained men without an acute increase in serum testosterone. Steroids. 2015;98:63-71. doi: 10.1016/j.steroids.2015.02.019 PMID: 25742735
41. Xu X, Zhan M, Duan W, Prabhu V, Brenneman R, Wood W, et al. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. Genome Biol. 2007;8:R234. doi: 10.1186/gb-2007-8-11-r234 PMID: 17988385
42. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol. 2008;8:581-593. doi: 10.1038/nri2360 PMID: 18617885
43. Gattinoni L, Ji Y, Restifo NP. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res. 2010;16:4695-4701. doi: 10.1158/1078-0432. CCR-10-0356 PMID: 20688898
44. Cao Dinh H, Beyer I, Mets T, Onyema OO, Njemini R, Renmans W, et al. Effects of physical exercise on markers of cellular immunosenescence: A systematic review. Calcif Tissue Int. 2016
45. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 2006;25:3479-3488. doi: 10.1038/sj.onc.1209386 PMID: 16449975
46. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer. 2008;98:1147-1156. doi: 10.1038/sj.bjc. 6604259 PMID: 18283316
47. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol. 2004;25:641-649. PMID: 15289865
48. Lagathu C, Christodoulides C, Tan CY, Virtue S, Laudes M, Campbell M, et al. Secreted frizzled-related protein 1 regulates adipose tissue expansion and is dysregulated in severe obesity. Int J Obes (Lond). 2010;34:1695-1705.
49. Wang M, Cheng N, Zheng S, Wang D, Hu X, Ren X, et al. Metabolic syndrome and the risk of breast cancer among postmenopausal women in north-west China. Climacteric. 2015;18:852-858. doi: 10. 3109/13697137.2015.1071346 PMID: 26507498
50. Bhandari R, Kelley GA, Hartley TA, Rockett IR. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int J Breast Cancer. 2014;2014:189384. doi: 10. 1155/2014/189384 PMID: 25653879
51. Mauro L, Naimo GD, Ricchio E, Panno ML, Ando S. Cross-Talk between Adiponectin and IGF-IR in Breast Cancer. Front Oncol. 2015;5:157. doi: 10.3389/fonc.2015.00157 PMID: 26236690
52. Giannopoulou I, Fernhall B, Carhart R, Weinstock RS, Baynard T, Figueroa A, et al. Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism. 2005;54:866-875. doi: 10.1016/j.metabol.2005.01.033 PMID: 15988694
53. Befort CA, Klemp JR, Austin HL, Perri MG, Schmitz KH, Sullivan DK, et al. Outcomes of a weight loss intervention among rural breast cancer survivors. Breast Cancer Res Treat. 2012;132:631-639. doi: 10.1007/s10549-011-1922-3 PMID: 22198470
54. DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol. 2011;29:7-10.